Description
Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027
Market Synopsis
Global Companion Diagnostics for Oncology Market is expected to witness a substantial market expansion at a CAGR of 22.57% during the review period of 2020 to 2027. The global market growth is attributed to rising R&D and drug-diagnostic co-development, increasing preference for personalized medicine, the growing global incidence of cancer, and rising product approvals by major players.
The global companion diagnostics for oncology market owing to the highest market value of USD 1,603.16 Million in 2019. Major market players are focusing on various growth strategies such as product launches, product expansion, and business expansions to serve the increasing demand for personalized medicine. These product launches and business expansion are expected to set the growth of the companion diagnostics for the oncology market during the review period. However, the lack of reimbursement in developing regions is expected to restrain the market growth during the review period.
Market Segmentation
Global Companion Diagnostics for Oncology Market has been classified into Products & Services, Technology, Indication, and End User.
Based on product & service, has been classified into assays, kits & reagents, and software & services.
In terms of technology type, the global companion diagnostics for the oncology market is classified into polymerase chain reaction (PCR) and next-generation sequencing (NGS).
In terms of indication segment, the global market has been categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. Based on end-user, the market is classified into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others.
Regional Analysis
Geographically, the Global Companion Diagnostics for Oncology Market is classified into four main regions, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the major share in 2019 and it is expected to command the market during the forecast period. The regional market is attributed to the high prevalence rate of cancer and other chronic disorders and growing healthcare expenditure.
Europe is expected to register the second-largest market share owing to the existence of many companies, rising research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine.
Asia-Pacific is anticipated to be the fastest-growing regional market during the review period owing to the increasing number of cancer patients and the growing presence of market players. Furthermore, the increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and rising awareness about personalized therapeutics in several APAC countries are expected to propel the growth of the Asia-Pacific market.
The Middle East & Africa is expected to register a steady market growth during the review period owing to the emerging market in countries such as Kuwait, the UAE, and Saudi Arabia.
Major Players
The Key Players in the Global Companion Diagnostics for Oncology Market include Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Global Radiation Therapy in the Oncology Market: Focus on Radiation Therapy Systems, Product Regulation, Key Strategies and Developments, Market Dynamics, 15 Company Profiles, and 12 Countries Data and Cross Segmentation – Analysis and Forecast, 2021-2031
Table of Contents
TABLE OF CONTENT 1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 16
1.2 MARKET ATTRACTIVENESS ANALYSIS 17
2 MARKET INTRODUCTION
2.1 DEFINITION 18
2.2 SCOPE OF THE STUDY 18
2.3 RESEARCH OBJECTIVE 18
2.4 MARKET STRUCTURE 18
2.5 ASSUMPTIONS & LIMITATIONS 19
3 RESEARCH METHODOLOGY
3.1 DATA MINING 20
3.2 SECONDARY RESEARCH 21
3.3 PRIMARY RESEARCH 22
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23
3.5 FORECASTING TECHNIQUES 24
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25
3.6.1 BOTTOM-UP APPROACH 26
3.6.2 TOP-DOWN APPROACH 26
3.7 DATA TRIANGULATION 27
3.8 VALIDATION 27
4 MARKET DYNAMICS
4.1 OVERVIEW 28
4.2 DRIVERS 29
4.2.1 RISING PREFERENCE OF PERSONALIZED MEDICINE 29
4.2.2 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS 29
4.2.3 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT 30
4.2.4 INCREASING GLOBAL INCIDENCE OF CANCER 30
4.3 RESTRAINTS 31
4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS 31
4.4 OPPORTUNITIES 32
4.4.1 ENTRY OF MARKET PLAYERS INTO EMERGING ECONOMIES 32
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 33
5.1.1 THREAT OF NEW ENTRANTS 33
5.1.2 BARGAINING POWER OF SUPPLIERS 34
5.1.3 THREAT OF SUBSTITUTES 34
5.1.4 BARGAINING POWER OF BUYERS 34
5.1.5 INTENSITY OF RIVALRY 34
5.2 SUPPLY CHAIN ANALYSIS 35
5.2.1 R&D AND DESIGNING 36
5.2.2 MANUFACTURING 36
5.2.3 DISTRIBUTION 36
5.2.4 MARKETING & SALES 36
5.2.5 POST-SALES MONITORING 36
5.3 IMPACT OF COVID-19 ON THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 36
5.3.1 OVERVIEW 36
5.3.2 IMPACT ON SUPPLY CHAIN 37
5.3.3 IMPACT ON PRODUCTION 37
5.3.4 IMPACT ON KEY PLAYERS 37
5.3.5 IMPACT ON REGIONS 37
6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES
6.1 OVERVIEW 38
6.2 ASSAYS, KITS & REAGENTS 39
6.3 SOFTWARE & SERVICES 40
7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY
7.1 OVERVIEW 41
7.2 POLYMERASE CHAIN REACTION (PCR) 42
7.3 NEXT-GENERATION SEQUENCING (NGS) 43
8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION
8.1 OVERVIEW 44
8.2 LUNG CANCER 46
8.3 BREAST CANCER 46
8.4 COLORECTAL CANCER 47
8.5 GASTRIC CANCER 47
8.6 MELANOMA 48
9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER
9.1 OVERVIEW 49
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 51
9.3 CONTRACT RESEARCH ORGANIZATIONS 51
9.4 LABORATORIES 52
10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION
10.1 OVERVIEW 53
10.2 AMERICAS 55
10.2.1 NORTH AMERICA 57
10.2.1.1 US 59
10.2.1.2 CANADA 60
10.2.2 LATIN AMERICA 62
10.3 EUROPE 64
10.3.1 WESTERN EUROPE 66
10.3.1.1 GERMANY 68
10.3.1.2 UK 70
10.3.1.3 FRANCE 71
10.3.1.4 ITALY 72
10.3.1.5 SPAIN 74
10.3.1.6 REST OF WESTERN EUROPE 75
10.3.2 EASTERN EUROPE 77
10.4 ASIA-PACIFIC 79
10.4.1 CHINA 81
10.4.2 JAPAN 82
10.4.3 INDIA 84
10.4.4 AUSTRALIA 85
10.4.5 SOUTH KOREA 87
10.4.6 REST OF ASIA-PACIFIC 88
10.5 MIDDLE EAST & AFRICA 90
10.5.1 MIDDLE EAST 92
10.5.2 AFRICA 93
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 95
11.2 COMPETITIVE BENCHMARKING 96
11.3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: COMPANY RANKING 97
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98
11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 98
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 99
11.6.1 PRODUCT APPROVALS AND LAUNCHES 99
11.6.2 JOINT VENTURES 102
11.6.3 EXPANSIONS 105
11.6.4 ACQUISITIONS 105
11.7 FINANCIAL MATRIX 106
12 COMPANY PROFILES
12.1 F. HOFFMANN-LA ROCHE LTD 107
12.1.1 COMPANY OVERVIEW 107
12.1.2 FINANCIAL OVERVIEW 108
12.1.3 PRODUCTS/SERVICES OFFERED 108
12.1.4 KEY DEVELOPMENTS 109
12.1.5 SWOT ANALYSIS 110
12.1.6 KEY STRATEGIES 110
12.2 THERMO FISHER SCIENTIFIC INC. 111
12.2.1 COMPANY OVERVIEW 111
12.2.2 FINANCIAL OVERVIEW 111
12.2.3 PRODUCTS/SERVICES OFFERED 112
12.2.4 KEY DEVELOPMENTS 112
12.2.5 SWOT ANALYSIS 113
12.2.6 KEY STRATEGIES 113
12.3 QIAGEN 114
12.3.1 COMPANY OVERVIEW 114
12.3.2 FINANCIAL OVERVIEW 114
12.3.3 PRODUCTS/SERVICES OFFERED 115
12.3.4 KEY DEVELOPMENTS 115
12.3.5 SWOT ANALYSIS 117
12.3.6 KEY STRATEGIES 117
12.4 BIOMÉRIEUX SA 118
12.4.1 COMPANY OVERVIEW 118
12.4.2 FINANCIAL OVERVIEW 118
12.4.3 PRODUCTS/SERVICES OFFERED 119
12.4.4 KEY DEVELOPMENTS 119
12.4.5 SWOT ANALYSIS 119
12.4.6 KEY STRATEGIES 119
12.5 ILLUMINA, INC. 120
12.5.1 COMPANY OVERVIEW 120
12.5.2 FINANCIAL OVERVIEW 120
12.5.3 PRODUCTS/SERVICES OFFERED 121
12.5.4 KEY DEVELOPMENTS 121
12.5.5 SWOT ANALYSIS 122
12.5.6 KEY STRATEGIES 122
12.6 ARCHERDX, INC. 123
12.6.1 COMPANY OVERVIEW 123
12.6.2 FINANCIAL OVERVIEW 123
12.6.3 PRODUCTS/SERVICES OFFERED 123
12.6.4 KEY DEVELOPMENTS 124
12.6.5 SWOT ANALYSIS 125
12.6.6 KEY STRATEGIES 125
12.7 FOUNDATION MEDICINE, INC. 126
12.7.1 COMPANY OVERVIEW 126
12.7.2 FINANCIAL OVERVIEW 126
12.7.3 PRODUCTS/SERVICES OFFERED 126
12.7.4 KEY DEVELOPMENTS 127
12.7.5 SWOT ANALYSIS 128
12.7.6 KEY STRATEGIES 128
12.8 AMOY DIAGNOSTICS CO. LTD 129
12.8.1 COMPANY OVERVIEW 129
12.8.2 FINANCIAL OVERVIEW 129
12.8.3 PRODUCTS/SERVICES OFFERED 129
12.8.4 KEY DEVELOPMENTS 130
12.8.5 SWOT ANALYSIS 131
12.8.6 KEY STRATEGIES 131
12.9 AGILENT TECHNOLOGIES, INC. 132
12.9.1 COMPANY OVERVIEW 132
12.9.2 FINANCIAL OVERVIEW 132
12.9.3 PRODUCTS/SERVICES OFFERED 133
12.9.4 KEY DEVELOPMENTS 133
12.9.5 SWOT ANALYSIS 134
12.9.6 KEY STRATEGIES 134
12.10 ABBOTT 135
12.10.1 COMPANY OVERVIEW 135
12.10.2 FINANCIAL OVERVIEW 135
12.10.3 PRODUCTS/SERVICES OFFERED 136
12.10.4 KEY DEVELOPMENTS 136
12.10.5 SWOT ANALYSIS 136
12.10.6 KEY STRATEGIES 137
13 APPENDIX
13.1 REFERENCES 138
13.2 RELATED REPORTS 138
